73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
A Almirall SA
A
Open
SectorHealthcare
13.36 -1.76
Overview
Share price change
24h
Min
13.32
Max
13.66
Income | 13M 21M |
|---|---|
Sales | -14M 260M |
P/E Sector Avg | 60.7 121.746 |
EPS | 0.1 |
Profit margin | 8.059 |
Employees | 2,026 |
EBITDA | 12M 66M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +5.42% upside |
Next Earnings | 23 Feb 2026 |
|---|
Market Cap | -80M 2.6B |
|---|---|
Previous open | 15.12 |
Previous close | 13.36 |
News Sentiment
By Acuity
14%
86%
11 / 352 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Almirall SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Almirall SA Forecast
Price Target
By TipRanks
5.42% upside
12 Months Forecast
Average 14 EUR 5.42%
High 14 EUR
Low 14 EUR
Based on 1 Wall Street analysts offering 12 month price targets forAlmirall SA - Dist in the last 3 months.
Sentiment
By Acuity
11 / 352 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Almirall SA
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Other stocks from the sector
Live chat